Anti-TNF Drug

PreclinicalSmall molecule

HHospices Civils de Lyon

Anti-TNF Drug is one of 51 small molecule programs targeting Complication. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseWithdrawn

Crohn's DiseasePreclinical

Withdrawn

Competition

Competitive Landscape

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

28 2

Humira

Novartis

Approved

22 3

Entyvio

Takeda

Approved

13 4

Omvoh

Eli Lilly

Approved

8 5

Trexall

Jazz Pharmaceuticals

Approved

1 6

Opzelura

Calciferol

Levulan

Sun Pharmaceutical Industries, Inc.

Lamprene

Rocaltrol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Crohn's Disease

NCT03681652

Clinical

Trials by Indication[1]

Crohn's Disease2 trials

Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease

Withdrawn·HHospices Civils de Lyon·N/A·NCT03712826

Post-Operative Crohn's Disease Outcome in Children

Recruiting·SSchneider Children's Medical Center, Israel··NCT03681652·100 enrolled

Complication1 trial

The Influence of Biologcal Treatment on the Short-Term Complications of Surgery in Patients With Inflematory Bowel Disease.

Completed·HHaEmek Medical Center, Israel··NCT03747068·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anti-TNF Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-TNF Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-TNF Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Anti-TNF Drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Crohn's Disease2 trials

Complication1 trial

References

Drug Info

Quick Facts

Related News